Enhanced cell killing induced by the combination of radiation and the heat shock protein 90 inhibitor 17-allylamino-17- demethoxygeldanamycin: a multitarget approach to radiosensitization.

No abstract is available for this paper.

• Publication year

  2003

• Venue

  Clinical Cancer Research

• Publication date

  2003-09-01

• Fields of study

  Biology, Medicine

• Identifiers
  PMID 14506167
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Solid Tumors

  2007cited by this paper
• 17-Allylamino-17-demethoxygeldanamycin induces the degradation of androgen receptor and HER-2/neu and inhibits the growth of prostate cancer xenografts.

  2002cited by this paper
• Independent prognostic significance of HER‐2 oncoprotein expression in pN0 prostate cancer undergoing curative radiotherapy

  2002cited by this paper
• Hsp90 inhibitors as novel cancer chemotherapeutic agents.

  2002influential reference
• Fusion Tyrosine Kinases Induce Drug Resistance by Stimulation of Homology-Dependent Recombination Repair, Prolongation of G2/M Phase, and Protection from Apoptosis

  2002influential reference
• Degradation of HER2 by ansamycins induces growth arrest and apoptosis in cells with HER2 overexpression via a HER3, phosphatidylinositol 3'-kinase-AKT-dependent pathway.

  2002cited by this paper
• Heat shock protein 90 inhibition by 17-allylamino-17- demethoxygeldanamycin: a novel therapeutic approach for treating hormone-refractory prostate cancer.

  2002cited by this paper
• Circulating Epstein-Barr virus DNA in serum of patients with lymphoepithelioma-like carcinoma of the lung: a potential surrogate marker for monitoring disease.

  2002cited by this paper
• Inhibition of radiation-induced nuclear factor-kappaB activation by an anti-Ras single-chain antibody fragment: lack of involvement in radiosensitization.

  2002cited by this paper
• The Ras radiation resistance pathway.

  2001cited by this paper
• Radiosensitization of p53 mutant cells by PD0166285, a novel G(2) checkpoint abrogator.

  2001cited by this paper
• Antiapoptotic activity is dispensable for insulin-like growth factor I receptor-mediated clonogenic radioresistance after gamma-irradiation.

  2001cited by this paper
• Inhibition of signal transduction by the Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin results in cytostasis and apoptosis.

  2001cited by this paper
• Modulation of Hsp90 function by ansamycins sensitizes breast cancer cells to chemotherapy-induced apoptosis in an RB- and schedule-dependent manner. See: E. A. Sausville, Combining cytotoxics and 17-allylamino, 17-demethoxygeldanamycin: sequence and tumor biology matters, Clin. Cancer Res., 7: 2155-

  2001cited by this paper
• Cytostasis and Apoptosis 17-Allylamino-17-demethoxygeldanamycin Results in Inhibition of Signal Transduction by the Hsp 90 Inhibitor Updated Version

  2001influential reference
• Disruption of the EF-2 kinase/Hsp90 protein complex: a possible mechanism to inhibit glioblastoma by geldanamycin.

  2001cited by this paper
• Monoclonal antibody to HER-2/neureceptor modulates repair of radiation-induced DNA damage and enhances radiosensitivity of human breast cancer cells overexpressing this oncogene.

  1999influential reference
• The benzoquinone ansamycin 17-allylamino-17-demethoxygeldanamycin binds to HSP90 and shares important biologic activities with geldanamycin

  1998cited by this paper
• Protein kinase B (c-Akt): a multifunctional mediator of phosphatidylinositol 3-kinase activation.

  1998cited by this paper
• Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents.

  1997cited by this paper
• Evidence supporting a signal transduction pathway leading to the radiation-resistant phenotype in human tumor cells.

  1997cited by this paper
• Discrimination of late apoptotic/necrotic cells (type III) by flow cytometry in solid tumors.

  1997cited by this paper
• A review of human cell radiosensitivity in vitro.

  1996cited by this paper
• Radioresistance induced by oncogenic transformation.

  1989cited by this paper
• Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.

  1987cited by this paper
• Mean inactivation dose: a useful concept for intercomparison of human cell survival curves.

  1984cited by this paper

• From radiation dose to cellular dynamics: A discrete model for simulating cancer therapy.

  2025cites this paper
• Radiation-induced effect of heat shock protein and potential clinical application

  2024cites this paper
• Peptide receptor radionuclide therapy in neuroendocrine neoplasms and related tumors: from fundamentals to personalization and the newer experimental approaches

  2023cites this paper
• Pharmacological inhibition of HSP90 radiosensitizes HNSCC xenograft by inhibition of DNA damage repair, nucleotide metabolism, and radiation-induced tumor vasculogenesis.

  2021cites this paper
• Retraction Retracted: Apoptosis and Molecular Targeting Therapy in Cancer

  2020cites this paper
• BVAN08 enhances radiosensitivity via downregulation of DNA-PKcs towards hepatic tumor xenograft

  2020cites this paper
• Radiation Modifiers.

  2019cites this paper
• 177Lu-octreotate therapy for neuroendocrine tumours is enhanced by Hsp90 inhibition

  2019cites this paper
• The Nuclear and DNA-Associated Molecular Chaperone Network.

  2019cites this paper
• The next generation of peptide receptor radionuclide therapy.

  2019cites this paper
• Radiosensitization of HSF-1 Knockdown Lung Cancer Cells by Low Concentrations of Hsp90 Inhibitor NVP-AUY922

  2019cites this paper
• ATM Is Required for the Prolactin-Induced HSP90-Mediated Increase in Cellular Viability and Clonogenic Growth After DNA Damage

  2018cites this paper
• Future Therapies in Medical Oncology

  2018cites this paper
• Sensitization of prostate cancer to radiation therapy: Molecules and pathways to target.

  2018cites this paper
• ENHANCING RADIATION SENSITIVITY IN NON-SMALL CELL LUNG CANCER

  2018cites this paper
• Hyperthermia‐mediated drug delivery induces biological effects at the tumor and molecular levels that improve cisplatin efficacy in triple negative breast cancer

  2018cites this paper
• Induction of Hsp70 in tumor cells treated with inhibitors of the Hsp90 activity: A predictive marker and promising target for radiosensitization

  2017cites this paper
• HSP90 inhibition sensitizes head and neck cancer to platin-based chemoradiotherapy by modulation of the DNA damage response resulting in chromosomal fragmentation

  2017cites this paper
• Evaluation of the radiosensitizing potency of chemotherapeutic agents in prostate cancer cells

  2017influential citation
• Translational research in radiation-induced DNA damage signaling and repair.

  2017cites this paper
• Bioluminescence Imaging to Monitor the Effects of the Hsp90 Inhibitor NVP-AUY922 on NF-κB Pathway in Endometrial Cancer

  2016cites this paper
• The effect of heat shock factor 1 (HSF-1) and heat shock proteins Hsp70 and Hsp27 on radiosensitivity and immunogenicity

  2016cites this paper
• Hsp90 Inhibitor Ganetespib Sensitizes Non–Small Cell Lung Cancer to Radiation but Has Variable Effects with Chemoradiation

  2016cites this paper
• Localization of MRP‐1 to the outer mitochondrial membrane by the chaperone protein HSP90β

  2016cites this paper
• Ganetespib radiosensitization for liver cancer therapy

  2016cites this paper
• Identification Of Novel Therapeutic Small-Molecule Inhibitors Of Dna Double-Stranded Break Repair

  2016cites this paper
• Hsp90: A New Player in DNA Repair?

  2015cites this paper
• Ganetespib: research and clinical development

  2015cites this paper
• The HSP90 Inhibitor Ganetespib Radiosensitizes Human Lung Adenocarcinoma Cells

  2015cites this paper
• The combination of Hsp90 inhibitor 17AAG and heavy-ion irradiation provides effective tumor control in human lung cancer cells

  2015cites this paper
• A SERS study of oxidation of glutathione under plasma irradiation

  2015cites this paper
• Targeting the heat shock response in combination with radiotherapy: Sensitizing cancer cells to irradiation-induced cell death and heating up their immunogenicity.

  2015influential citation
• Hsp90 inhibitor as a sensitizer of cancer cells to different therapies (review).

  2014cites this paper
• Radiosensitization of human lung cancer cells by the novel purine-scaffold Hsp90 inhibitor, PU-H71.

  2014cites this paper
• Down-regulation of Heat Shock Protein HSP90ab1 in Radiation-damaged Lung Cells other than Mast Cells

  2014cites this paper
• Radiation and Altering Clinical Pharmacology

  2014cites this paper
• Targeting the heat shock protein 90 with the novel small-molecule inhibitor NW457 sensitizes tumor cells to ionizing radiation

  2014cites this paper
• The HSP90 inhibitor ganetespib has chemosensitizer and radiosensitizer activity in colorectal cancer

  2014cites this paper
• Apoptosis and Molecular Targeting Therapy in Cancer

  2014cites this paper
• Current concepts in clinical radiation oncology

  2013cites this paper
• The HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin modulates radiosensitivity by downregulating serine/threonine kinase 38 via Sp1 inhibition.

  2013cites this paper
• Enhancing radiation therapy for patients with glioblastoma

  2013cites this paper
• Prospective study of prognostic value of Raf kinase inhibitory protein and pretreatment plasma Epstein–Barr virus DNA for distant metastasis in locoregionally advanced nasopharyngeal carcinoma

  2013cites this paper
• Molecularly Targeted Agents as Radiosensitizers in Cancer Therapy—Focus on Prostate Cancer

  2013cites this paper
• Preclinical evaluation of radiosensitizing activity of Pluronic block copolymers

  2013cites this paper
• Modulation of radiosensitivity of human tumor and normal cells by inhibition of heat shock proteins Hsp90 and Hsp70

  2013cites this paper
• Radiosensitization of Normoxic and Hypoxic H1339 Lung Tumor Cells by Heat Shock Protein 90 Inhibition Is Independent of Hypoxia Inducible Factor-1α

  2012cites this paper
• Hyperthermia-induced DNA repair deficiency suggests novel therapeutic anti-cancer strategies

  2012cites this paper
• Cancer Therapy : Preclinical Darinaparsin : Solid Tumor Hypoxic Cytotoxin and Radiosensitizer

  2012cites this paper
• Novel Hsp90 inhibitor NVP-AUY922 radiosensitizes prostate cancer cells

  2012cites this paper
• The HSP90 Inhibitor NVP-AUY922 Radiosensitizes by Abrogation of Homologous Recombination Resulting in Mitotic Entry with Unresolved DNA Damage

  2012influential citation
• Hsp90 Inhibitors NVP-AUY922 and NVP-BEP800 May Exert a Significant Radiosensitization on Tumor Cells along with a Cell Type-Specific Cytotoxicity.

  2012cites this paper
• Hsp90 inhibitor NVP-AUY922 enhances radiation sensitivity of tumor cell lines under hypoxia

  2012cites this paper
• Hsp90 Inhibitors are Promising Radiosensitizers for Radiotherapy

  2012cites this paper
• Darinaparsin: Solid Tumor Hypoxic Cytotoxin and Radiosensitizer

  2012cites this paper
• The molecular genetics and tumor pathogenesis of meningiomas and the future directions of meningioma treatments.

  2011cites this paper
• Low-dose Hsp90 inhibitors tumor-selectively sensitize bladder cancer cells to chemoradiotherapy

  2011cites this paper
• Enhancement of radiation sensitivity in lung cancer cells by celastrol is mediated by inhibition of Hsp90.

  2011cites this paper
• Enhancement of radiosensitivity in human glioblastoma cells by the DNA N-mustard alkylating agent BO-1051 through augmented and sustained DNA damage response

  2011cites this paper
• Role for NAD(P)H:quinone Oxidoreductase 1 and Manganese-Dependent Superoxide Dismutase in 17-(Allylamino)-17-demethoxygeldanamycin-Induced Heat Shock Protein 90 Inhibition in Pancreatic Cancer Cells

  2011cites this paper
• Inhibitors of heat shock protein 90 activity: A novel class of tumor radiosensitizers

  2011cites this paper
• The molecular genetics and tumor pathogenesis of meningiomas and the future directions of meningioma treatments

  2011cites this paper
• CHAPTER 56 – Chemotherapy and Experimental Medical Therapies for Meningiomas

  2010cites this paper
• Hsp90 as a Gatekeeper of Tumor Angiogenesis: Clinical Promise and Potential Pitfalls

  2010cites this paper
• Hsp90 inhibitors as promising agents for radiotherapy

  2010cites this paper
• Inhibitors of glucose and hydroperoxide metabolism potentiate 17AAG-induced cancer cell killing via metabolic oxidative stress

  2010cites this paper
• Molecular biology of squamous cell carcinoma of the head and neck: relevance and therapeutic implications

  2010cites this paper
• Medical therapies for meningiomas

  2010cites this paper
• Novel HSP90 inhibitors, NVP-AUY922 and NVP-BEP800, radiosensitise tumour cells through cell-cycle impairment, increased DNA damage and repair protraction

  2010cites this paper
• Development and study of inhibitors of heat shock protein 70 induction

  2010cites this paper
• Efficacy of the HSP90 inhibitor 17-AAG in human glioma cell lines and tumorigenic glioma stem cells.

  2009cites this paper
• Inhibition of heat shock induction of heat shock protein 70 and enhancement of heat shock protein 27 phosphorylation by quercetin derivatives.

  2009cites this paper
• Targeting heat shock protein 90 overrides the resistance of lung cancer cells by blocking radiation-induced stabilization of hypoxia-inducible factor-1alpha.

  2009cites this paper
• Acquired resistance to 17-allylamino-17-demethoxygeldanamycin (17-AAG, tanespimycin) in glioblastoma cells.

  2009cites this paper
• Molecular targets for tumor radiosensitization.

  2009cites this paper
• Hsp90 is expressed and represents a therapeutic target in human oesophageal cancer using the inhibitor 17-allylamino-17-demethoxygeldanamycin

  2009cites this paper
• HSP90 inhibitors: multi-targeted antitumor effects and novel combinatorial therapeutic approaches in cancer therapy.

  2009cites this paper
• An experimental study on the antitumor effect of 131I-17-AAG in vitro and in vivo

  2009cites this paper
• Enhanced radiation-induced cell killing by Herbimycin A pre-treatment

  2009cites this paper
• BIIB021, a novel Hsp90 inhibitor, sensitizes head and neck squamous cell carcinoma to radiotherapy

  2009cites this paper
• Overview of cancer molecular radiobiology.

  2008cites this paper
• Oxidative stress plays a critical role in inactivating mutant BRAF by geldanamycin derivatives.

  2008cites this paper
• Heat shock proteins in animal neoplasms and human tumours—a comparison

  2008cites this paper
• Inhibition of Hsp90 Leads to Cell Cycle Arrest and Apoptosis in Human Malignant Pleural Mesothelioma

  2008cites this paper
• Radiosensitization of human vascular endothelial cells through Hsp90 inhibition with 17-N-allilamino-17-demethoxygeldanamycin.

  2008cites this paper
• Heat shock protein 90 inhibition is cytotoxic to primary AML cells expressing mutant FLT3 and results in altered downstream signalling

  2008cites this paper
• Inhibition of Hsp90: A Multitarget Approach to Radiosensitization

  2007cites this paper
• Inhibition of Hsp 90 : AMultitarget Approach to Radiosensitization

  2007cites this paper
• Enhanced lung cancer cell killing by the combination of selenium and ionizing radiation.

  2007cites this paper
• Survivin, a member of the inhibitor of apoptosis family, is induced by photodynamic therapy and is a target for improving treatment response.

  2007cites this paper
• INVOLVEMENT OF HEAT SHOCK PROTEINS IN PROTECTION OF TUMOR CELLS FROM GENOTOXIC STRESSES

  2007cites this paper
• Targeted drug therapy for meningiomas.

  2007cites this paper
• In vitro combined modality treatment of prostate carcinoma cells with 17-(allylamino)-17-demethoxygeldanamycin and ionizing radiation.

  2006cites this paper
• Inhibition of homologous recombination repair in irradiated tumor cells pretreated with Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin.

  2006cites this paper
• P53-dependent radiosensitizing effects of Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin on human oral squamous cell carcinoma cell lines.

  2006cites this paper
• Hsp90 inhibitors cause G2/M arrest associated with the reduction of Cdc25C and Cdc2 in lung cancer cell lines

  2006cites this paper
• Inhibition of hsp90 compromises the DNA damage response to radiation.

  2006cites this paper
• Novel therapies for meningiomas

  2006cites this paper
• Targeting the androgen receptor as a therapeutic strategy for prostate cancer.

  2006cites this paper
• Hsp90: a novel target for cancer therapy.

  2006cites this paper